scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.AHJ.2010.04.022 |
P698 | PubMed publication ID | 20598967 |
P50 | author | Harvey White | Q1587897 |
Dorairaj Prabhakaran | Q37390473 | ||
Matthew T Roe | Q64684757 | ||
Yuliya Lokhnygina | Q82040206 | ||
P2093 | author name string | Eileen Brown | |
Paul W. Armstrong | |||
Chee Tang Chin | |||
E. Magnus Ohman | |||
Keith A.A. Fox | |||
Helene Petitjean | |||
Debra A. Marshall | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
clopidogrel | Q410237 | ||
myocardial infarction | Q12152 | ||
P304 | page(s) | 16-22.e1 | |
P577 | publication date | 2010-07-01 | |
P1433 | published in | American Heart Journal | Q2227156 |
P1476 | title | Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY | |
P478 | volume | 160 |
Q38475429 | A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel |
Q38391208 | A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention |
Q37998114 | Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines |
Q41620962 | Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack. |
Q38101275 | Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents |
Q35752619 | Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q37914924 | Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents |
Q37965609 | Antiplatelet therapy in acute coronary syndromes. |
Q37997963 | Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus |
Q39161550 | Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial |
Q36484993 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome |
Q39768278 | Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial |
Q90146028 | Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome |
Q57243374 | Atherothrombosis and the role of antiplatelet therapy |
Q37403998 | Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes |
Q45894982 | Contemporary roles of registries in clinical cardiology: when do we need randomized trials? |
Q37913974 | Cost-effectiveness of oral antiplatelet agents--current and future perspectives |
Q90613054 | Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes |
Q38005018 | Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials |
Q39550267 | Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. |
Q55074433 | Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. |
Q40825574 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients |
Q37949587 | Emerging therapies for acute coronary syndromes |
Q50279616 | Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial |
Q35135852 | Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome |
Q41528609 | Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial |
Q38025446 | Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel |
Q36141930 | Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes |
Q42185272 | Oral antiplatelet therapy in acute coronary syndromes: update 2012. |
Q39635786 | Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention |
Q37969927 | P2Y12 platelet inhibition in clinical practice |
Q51539033 | P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome. |
Q82791112 | Percutaneous coronary intervention in the elderly |
Q38084549 | Perioperative management of antiplatelet therapy in patients with drug-eluting stents. |
Q37142852 | Personalized vascular medicine: individualizing drug therapy |
Q38113231 | Pharmacokinetic considerations for antithrombotic therapies in stroke |
Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
Q57252716 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial |
Q37907902 | Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? |
Q57243369 | Quelle place pour les nouveaux anti-agrégants plaquettaires dans la stratégie thérapeutique ? |
Q35067126 | Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting |
Q37556037 | Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes |
Q37953259 | Role of antiplatelet therapy in secondary prevention of acute coronary syndrome |
Q36163681 | ST Elevation Myocardial Infarction in the elderly |
Q37925009 | TRITON and beyond: new insights into the profile of prasugrel |
Q26829746 | The year in non-ST-segment elevation acute coronary syndrome |
Q41817424 | Towards personalized medicine based on platelet function testing for stent thrombosis patients |
Q38005621 | Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? |
Search more.